Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

This content has been developed for healthcare professionals only.
Patients who seek health information should consult with their
physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides,
and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply
for credit, please visit us at PeerView.com/EGP865.
CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until
December 12, 2024.


Equitably Empowering Our Upper GI Cancer Patients Using Plain
Language Tools to Improve Outcomes With Immunotherapeutic
Regimens Through Informed Shared Decision-Making


In support of improving patient care, PVI, PeerView Institute for
Medical Education, is jointly accredited by the Accreditation
Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the
American Nurses Credentialing Center (ANCC), to provide
continuing education for the healthcare team.


SupportThis activity is supported through
an educational grant from Bristol Myers Squibb.


Disclosure Policy
All relevant conflicts of interest have been mitigated prior to
the commencement of the activity.


Faculty/Planner
DisclosuresChair/Planner
Yelena Y. Janjigian*, MD, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen;
Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.;
AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation;
Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline;
Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck
& Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer;
Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS
Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for
Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.;
Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer
Institute; Transcenta Holding; and U.S. Department of
Defense.
Stock Shareholder in Inspirna, Inc.


Planning Committee and Reviewer
DisclosuresPlanners, independent reviewers, and
staff of PVI, PeerView Institute for Medical Education, do not
have any relevant financial relationships related to this CE
activity unless listed below.